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PROPOSED BIOLOGICAL EVALUATION OF FDA-APPROVED DRUGS AS MIRNA-31 INHIBITORS USING REAL
TIME QRT-PCR AND A LUCIFERASE ASSAY

Nicholas Sienkiewicz, B.S., B.M.A.

Western Michigan University, 2020
Abstract: Overexpression of miRNA-31 has been shown to play an essential role in the genesis and
development of colorectal cancer (CRC), as well as drug resistance to approved CRC drug therapies (5FU). The goal of this research was to identify a small molecule inhibitor of miRNA-31 expression by
repurposing an FDA approved drug. The compounds were identified using the Psmir database which
predicts associations between small molecule compounds and miRNA expression. 14 FDA-Approved
drugs were selected and methods for their evaluation were proposed. A luciferase assay for the primary
evaluation of miRNA-31 expression still requires optimization, but the expression and purification of the
miRNA-31 pmirGLO and empty vector were completed. An optimized qRT-PCR assay for secondary
evaluation of miRNA-31 expression was completed, finding miRNA-16 and miRNA-93 as suitable
housekeeping genes for qRT-PCR normalization.
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CHAPTER I: INTRODUCTION
1.1. MicroRNAs
MicroRNAs (miRNAs) are a group of post-transcriptional, negative regulators of gene expression,
consisting of ~19-24 nucleotides. They were first discovered in 1993 at Harvard University when
researchers were investigating the lin-4 gene in C. elegans.1 The first miRNA observed in mammals was
in the let-7 gene of C.elegans.2 After a search using the basic local alignment search tool (BLAST), the
same sequence was revealed to be an exact match to mature let-7 in D. melanogaster and human
genomes.3 Let-7 is not often studied, as its interaction with LIN28B, a proto-oncogene, is still unknown.4
miRNAs function by binding to the 3’ untranslated region (3’ UTR) of a target mRNA, resulting in either
destabilization or complete degradation of the mRNA and subsequent inhibition of translation.
MicroRNAs have been detected in a wide variety of animal models and considerably conserved across
species.5-9
The non-canonical pathways are grouped into
Drosha/DGCR8-independent and Dicer-independent pathways.
Those pre-miRNAs that are generated via the Drosha/DGCR8pathway resemble Dicer substrates, such as mirtrons.10-11 Dicerindependent pre-miRNAs are processed via Drosha from short
hairpin RNA (shRNA) transcripts. These require AGO2 to be fully
processed, as they are too small to be Dicer substrates.12 This
pathway also results in mature miRNA, which is then used to
regulate gene expression.
miRNAs regulate gene expression via the miRNA-induced
silencing complex (miRISC). It recognizes specific miRNAs via
miRNA response elements (mRNEs). A perfectly complementary

Figure 1.1. Canonical biogenesis
pathway of miR. (borrowed from
Van Meter, E.N, et al., 2020)
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interaction results in AGO2 endonuclease activity, resulting in mRNA cleavage.13-15 In humans, most of
the interactions between miRISC and mRNEs are not perfectly complementary. Consequently, the
miRISC complex operates as a meditator of RNA interference.
1.2. miRNA-31
miRNA-31 is a highly conserved transcriptional regulator that has been found to play a role in
many cellular processes. Its gene is located on the 9p21.3 (chr9:21502114–21502184) near the p16-Arfp15 locus. The p16 gene is considered a tumor suppressor gene and has antiproliferative biological
activity. Mutation and/or deletion of this essential gene have been evaluated in many different types of
cancers.16-18 MiRNA-31’s role in cancer cell proliferation is context dependent, meaning it can act as
either as a tumor-suppressor or oncogenic gene. As seen in Figure 1.2, the normal function of tumor
suppressor miRNAs is to target mRNA that produce proteins involved in cancer promoting pathways. If
tumor suppressor miRNAs are decreased in the tissue due to dysregulation of the cell, then malignancies
will occur. Conversely, oncogenic miRNA inhibits the production of proteins that stop cancer growth,
therefore when overexpressed they promote tumor growth and invasion to surrounding tissue.

Figure 1.2. Comparison of oncogenic miRNA and tumor suppressor miRNA. (borrowed from Cailin, et. al, 2006)
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In breast cancer, miRNA-31 is heavily down-regulated and acts as a tumor suppressor.19 miR-31
prohibits various pathways essential to the survival of cancer. For instance, miR-31 target genes WASF3,
RHOA, and ITGB produce proteins that enable cell motility; while GNA13 and PKC allows for cell
invasion.20-23 It is also downregulated in certain leukemias, glioblastomas, hepatocellular carcinoma,
ovarian cancer, and bladder cancer.24-29 In other cases, as in the case with colorectal cancer, miRNA-31
acts as an oncogene and has been shown to be upregulated in many cell types. In one study, miRNA-31
was found to be up-regulated in 91% of a set of 98 colorectal cancer samples.30
1.3 Colorectal Cancer and miRNA-31
Currently, colorectal cancer (CRC) is the third leading cause of cancer-related death in the
United States and the third most common cancer in men and women.31 Due to the improved early
detection methods, the five-year survival rate for localized colorectal cancer in the United States is at
90%. However, if the disease is not detected early and metastasizes (distant), the five-year survival rate
falls to 14%.32 The current treatment for the disease includes excision of the tumor site, chemotherapy,
and radiation. For chemotherapy, 5-fluorouracil (5-FU) has been the choice drug in treating the disease.
5-FU functions as a thymidylate synthase (TS) inhibitor to interrupt the action of this enzyme (citation).
By doing so, it blocks the synthesis of the pyrimidine thymidine, a nucleoside required for DNA
replication. The side effects of this treatment include hair loss, nausea and vomiting, sores of the mouth,
and decreased a decreased white cell count. As patients are continually exposed to the medication, it
often results in chemoresistance leading to a relapse in the colorectal cancer.
Recent findings have suggested that miRNAs play a significant role in every stage of CRC
initiation, progression, and development, as well as induce resistance to chemotherapy drugs like 5FU.33 In particular, research has shown that increased levels of miRNA-31 cause 5-FU resistance in CRC
and that suppression of miRNA-31 expression will increase the sensitivity of CRC cells to 5-FU increasing
the likelihood of survival of patients, especially in the case of relapse in the cancer. 34-35

4
1.4 Drug Discovery and miRNA
Currently, there are multiple strategies in order to disrupt miRNA function. These include miRNA
sponges, antisense oligonucleotides (ASOs), CRISPR and small molecule modulators. Each therapeutic
strategy reaps its own benefits and disadvantages in terms of disrupting miRNA activity.
miRNA Sponges
miRNA sponges are RNA transcripts that can associate with specific miRNA’s via high affinity
binding sites, which prevent them from interacting their target mRNAs. Generally, the miRNA binding
sites (MBS) are separated by 4-6 nucleotides. These sites are either antisense to the specific miRNA or
contain a bulge. The sponges that contain the central bulge are most effective, as perfectly antisense
sequences are prone to interference and degradation.36
The benefit of this sort of technology is the ability to inhibit multiple miRNAs, possibly a whole
family, with multiple binding sites. Furthermore, it presents specific advantages over something like an
oligonucleotide. Generally, oligonucleotides are difficult to uptake by the cell and require specific
reagents and tedious optimization. Sponges can easily be introduced by a viral vector. The vector can
include a selectable marker, making it simple to choose cells that have uptake the vector. Moreover,
continuous dosing of oligonucleotides is necessary for long-term efficacy. However, given sponges
operate via a vector, they can continuously be generated within the cell.
Given the large number of binding sites, and the relatively small number of nucleotides for
miRNAs, there is the potential for nonspecific interactions with miRNAs that were not intended to be
sequestered. Careful optimization is required to make sure that nonspecific miRNA binding does not
occur.37 The most significant factor is concentration. If the miRNA concentration is very high, titrations
of the sponge must also be considerably large.
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These sponges have been successfully used to study the role of miRNA-31 in certain cancers. In a
study by Valstyn et al., experimenters transduced nonmetastatic breast cancer cells with retroviral eGFP
sponges for miR-31 in mouse mammary fat pads.38 Compared to the negative control, the miR-31
sponge containing tumors metastasized to the lungs of the mouse, forming 10x more lesions, measured
by GFP fluorescence. This led researchers to conclude that miRNA-31 in nonmetastatic breast cancer
was a tumor suppressor.
Antisense Oligonucleotides (ASOs)
ASOs are a fairly practical approach to miRNA modulation. Essentially, the oligonucleotides are
designed with a sequence that is the complement to the miRNA of interest. The target miRNA then
becomes tightly bound to the oligonucleotides, where it will eventually be degraded by the cell.
Although seemingly straightforward, there are many limitations to the use of antisense
oligonucleotides. ASOs require the use of expensive transfection reagents to introduce them to cells.
Furthermore, AOSs are chemically unstable in the cell and require tedious optimization in order to
determine the correct concentration, and more importantly the time of the inhibitor exposure. Although
ASOs are successful at inhibiting mature miRNA, they are unable to inhibit precursor miRs, limiting them
to a single step biogenesis pathway to exert activity. As a drug, ASOs suffer from poor delivery efficiency
and tissue distribution. In human subjects, they have been found to have more serious side effects due
to off-target effects.39-40 Improvement of ASO specificity is an active research topic. In particular
specialized formulations enable precise delivery of the ASO to a specific tissue/mRNA target has helped
increase the therapeutic relevance of ASOs.41 Several ASOs therapies have since been approved by the
FDA for various diseases.42 As of 2017, these include Vitravene, Macugen, Kynamro, Eteplirsenn,
Defitelio, and Spinraza. These ASOs have been used to treat a wide variety of conditions, including
cytomegalovirus (CMV) retinitis, age-related macular degeneration (AMD), homozygous familial
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hypercholesterolemia (HoFH), Duchenne muscular dystrophy (DMD), severe hepatic veno-occlusive
disease (sVOD), and infant spinal muscular atrophy, respectively.
CRISPR
The use of CRISPR (clustered regulatory interspaced short palindromic repeats) technology has
gained widespread attention for its potential use in treating genetically related disorders. The system for
gene editing is composed of CRISPR, Cas9, an endonuclease from S. pyrogenes, and a guide RNA. The
system operates by guide RNA binding to a specific sequence on the target DNA, along with binding to
Cas9. Cas9 then cuts the DNA at the targeted location. Then, using the cell’s own repair machinery, the
DNA sequence can be changed, deleted, or replaced by a customize sequence. Research has shown that
this technology can be used in order to knock down miRNA expression levels both in vivo and in vitro.43
This is accomplished by targeting the terminal loop, or 5’ region of the pre-miRNA, or by targeting the
secondary loop structures of primary miRNAs. The CRISPR/cas9 system has been shown to decrease the
expression levels stably in cells for up to 30 days.
The most significant disadvantages of this technology are the ethical concerns raised by genome
editing and the issue of “off-target” modifications. Because the cells use their own repair machinery,
additional mutations, duplications, or deletions could potentially affect the DNA sequence that is being
targeted.44-45 In humans it is unknown what affect these modifications could have on the complex
biochemical processes that occur in the body. Mosaicism is also a significant concern.46 This occurs when
some cells retain the edit, but other cells do not.
Small Molecules
Small molecule compounds are viewed as an ideal solution for developing inhibitors. These
compounds have many distinct advantages, over the previously mentioned miRNA-targeting therapeutic
strategies. Small molecules drugs can be easily designed to be easily delivered and permeate the cell
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membranes through traditional medicinal chemistry efforts. Small molecules can target any part of the
miRNA biogenesis pathway either through direct engagement to the stem-looped pri- or pre- miRNA
structures or auxiliary proteins that facilitate miRNA biogenesis.47-48 Much is still being learned about the
design of small molecules that modulate miR activity. For one, pri- and pre- miRNA do not have complex
tertiary structure like proteins, therefore, the medicinal chemistry “rules” for designing drug-like
molecules that target the secondary structure motifs of miRNA are still being defined.
1.5 Current Status of miRNA-31 targeting small molecules
Currently, there are few compounds that have been shown to modulate miRNA-31 activity.
Among these compounds are aminosulfonylarylisoxazole analogues, as identified by Im et. al, shown in
Figure 1.3.

Figure 1.3. Aminosulfonlyarylisoxazole analogues. “R” and “R1R2” represent areas in which additional
functional groups may be added (borrowed from Im et. al, 2017)

Three analogues of this compound have been shown to selectively inhibit miRNA-31 activity, as
shown in Figure 1.3. Compound 1 represents the aminosulfonlyarylisoxazole scaffold upon which
compounds 2-4 were synthesized. Compounds 2 and 4 specifically inhibited the expression of miRNA-31,
while not affecting other miRNAs tested which included. Compound 3 significantly lowered the
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expression levels of miRNA-21. Reduction in the target mRNAs of miRNA-31 including STK40, E2F2, and
PPP2R2A was also shown. It was found that these compounds affected the maturation of miRNA-31 into
mature miRNA from pri- and pre-miRNA-31. Similar inhibitory effects were observed when treated with
a miRNA-31 mimic, when compared to the compounds.49

1.6 Drug Repurposing
Drug repurposing (repositioning) involves redeveloping a drug compound for use in a different
disease.50 The repurposing of these compounds is advantageous, as FDA-approved drugs have detailed
information relating to their pharmacology, formulation, dose, and toxicity.51 Moreover, these drugs are
generally more accessible for purchase, rather than having to be synthesized directly. The differentiated
use of these compounds also results in decreased cost and less development time.
The targeting of RNAs as a therapeutic strategy has become increasingly understood. RNA is a
key drug target, as it is upstream of many pathological mechanisms involved in disease states.52-53 In
relation to miRNA, drug repurposing is especially relevant. Numerous FDA drugs that have been
designed to target protein to promote a biological effect are typically evaluated for off-target effects
and selectivity against similar proteins. However, it has become increasingly evident that these proteintargeting drugs also affect miRNA expression. For instance, Tamoxifen, Cisplatin, 5-FU, and Docetaxel
have been shown to modulate miRNA levels in drug resistant breast cancer cell lines.54
CHAPTER II: IDENTIFICATION OF POTENTIAL MIRNA-31 INHIBITORS USING Psmir COMPUTATIONAL
TOOL
2.1 Introduction: Psmir Base
Psmir is a large-scale database that uses computational mathematics to predict small moleculemiRNA associations via comparison of current gene expression profiles. The database was created by
Fanlin Meng et. al at Harbin Medical University.55 The database predicts associations of small molecules
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with specific miRNA and scores them from-1.0 to 1.0. The closer the number is to -1.0, the more potent
of an inhibitor of miRNA-31. In order to calculate these values, the researchers collected gene
expression profiles using keywords including “miRNA transfection” and “microRNA transfection” from
the Gene Expression Omnibus (GEO) database. Moreover, small molecule-perturbed gene expression
profiles were obtained from the Connectivity Map (cmap). Probes were screened if they could be
perturbed by one small molecule or one miRNA, which then translated to the degree of probes
perturbed by one small molecule, or miRNA over the entire expression profile.
The size of the score itself related to the similarity between the small molecule and the miRNA.
These scores were combined between the same small molecule and miRNA. This data was then
compiled into the Psmir databse. Each listed compound includes the chemical name, whether it is FDA
approved, the miRNA it interacts with, the gene the miRNA regulates, the score, p-value, and a link for
further details. An example of a compound is shown in Figure 2.1 below.

Figure 2.1. Example of information provided by psmir during searches. Aminophenazone was identified as a
miRNA-31 inhibitor, is FDA approved, with a score close to -1 meaning it is a good inhibitor based on the
program.

2.2. Results using Psmir
Compounds were selected based on their ability to inhibit miRNA-31, along with FDA approval.
Table 1 below outlines the compounds selected, with their current FDA approved uses.
Table 1. List of miRNA-31 inhibitors identified by psmir, their FDA approved purpose, scores, and NCI numbers.
Compounds
Current Role
*Score Value

NCI #

Aminophenazone

Analgesic

-0.619

4993

Chlorpromazine

Antipsychotic

-0.302

167745
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Clotrimazole

Antifungal

-0.585

257473

Hydroxyzine

Anxiety disorders and Allergic Conditions

-0.511

169188

Methantheline bromide

Antimuscarinic agent (anticholinergic)

-0.589

32145

Metyrapone

Glucocorticoid synthesis inhibitor

-0.615

25265

Nitrofurantoin

Antibiotic

-0.568

44150

Phenazone

Non-narcotic analgesic, antipyretic and NSAID

-0.794

7945

Physostigmine

Anticholinergic agent

-0.717

30782

Procyclidine

Muscarinic antagonist

-0.607

169103

Raloxifene

Selective estrogen receptor modulator

-0.468

747974

Rescinnamine

Antihypertensive

-0.645

15628

Riluzole

Antidepressant

-0.562

759823

Trimethadione

Anticonvulsive and antiepileptic

-0.599

169503

*Scores closer to -1 estimated as more potent inhibitors of miR-31

The small molecule compounds identified in the Psmir database were requested from the
Developmental Therapeutics Program though the National Institutes of Health National Cancer Institute
(NIH NCI). Not all compounds were available through this program, resulting in 14 compounds for
analysis. They arrived in solid form and were serially diluted at a 1:3 for future studies. Structures for the
compounds are shown in Figure 2.2.
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Figure 2.2. Compound structures identified at miR-31 inhibitors in psmir. Compounds will be tested in
cell-based assays in the future.

2.3. Conclusions
The compounds listed in Figure 2.2 were chosen based on their perceived ability to inhibit
miRNA-31, FDA-approval, and their availability from NCI. Although there are no biochemical assays that
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evaluated their potency, the mathematical relationship that exists between these compounds and their
ability to inhibit miRNA-31 is the foundation for what this project explores. Although the data from
biochemical assays has yet to be understood, these compounds will serve as the test compounds for
future experiments, as outlined in this paper. The compounds are expected to show activity based on
the theoretical approach taken by the creators of psmir base. As showcased in Figure 2.2, every
compound has a nitrogen containing region. This generates a positive electrostatic charge, which would
allow them to interact with the negatively charged miRNA.
CHAPTER III: EVALUATION OF SMALL MOLECULE COMPOUND MODULATION OF miRNA-31
EXPRESSION LEVELS USING A LUFICERASE ASSAY
3.1. Background
The luciferase assay has been used for the detection of mature miRNA since its first use by
Deiters et. al in 2008. However, Deiters et. al utilized the psiCHECK vector, whereas this experiment uses
the pmirGLO vector. Briefly, the reverse complement of the miR of interest was inserted downstream of
a firefly luciferase gene, which contains the miR binding sequence (Figure 3). Without an inhibitor, the
miRNA of interest can bind to the miR-binding sequence in the reporter plasmid thus inhibiting
translation of the luciferase gene (Figure 3.1.A). Without the luciferase enzyme being produced,
bioluminescence will not be observed even in the presence of luciferase substrates. In the presence of
an inhibitor (Figure 3.1.B), the miRNA does not bind to the miRNA-binding sequence, therefore, allowing
for translation and production of luciferase and a measurable signal of bioluminescence when
substrates are introduced.

Figure 3.1 Luciferase-based assay for detecting miR expression. A) Upon the binding of miRNA-31 to its miRNA
response element on its target mRNA, the luciferase gene is unable to be translated. B) A small molecule
inhibitor of miRNA-31 allows for luciferase translation and the measurement of luminescence.
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This use of luciferase technology for miRNA expression analysis allows for investigation of small
molecule that may act upon any part of the miRNA biogenesis pathway. This means a small molecule
could be inhibiting the expression of miRNA-31 by targeting a protein along the pathway or directly
interacting with the stem-looped structure of pri- or pre-miRNA-31.
We have chosen to use the pmirGLO vector (Promega) to construct our pmirGlo-miRNA-31
reporter plasmid because it contains both Firefly and Renilla luciferase genes which allows for
normalization of signal account replicates and account for extraneous variables affecting the validity of
each assay. As seen in Figure 3.2, the Firefly luciferase reporter enzyme requires D-luciferin, ATP, O2,
and Mg2+ to produce bioluminescence and resulting products (oxyluciferin, PPi, AMP, and CO2) while the
Renilla luciferase enzyme needs coelenterazine and O2 to produce bioluminescence and coelenteramide
and CO2 products. This works to our advantage because the Firefly luciferase substrates can be added
first and bioluminescence read followed by the addition of Renilla luciferase substrate and the
quantification its light product. Our compounds should only affect the translation of the reporter gene,
firefly luciferase, and not Renilla luciferase. Note: Due COVID-19 and the shutting down of research labs,
the experimental procedures discussed below is proposed based on literature and will be tested by
future researchers.
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Figure 3.2. Firefly luciferase substrates vs Renilla luciferase substrates. The Firefly luciferase enzyme
requires different substrates than the Renilla luciferase making them ideal for normalization in a Dual
Luciferase study. (Image borrowed from Promega)

3.2. Experimental Procedure
3.2.1. General reagents and instrumentation for experiments (proposed)
Small molecules identified in Psmir database were requested from the Developmental
Therapeutics Program though the National Institutes of Health National Cancer Institute (NIH NCI). Small
molecules (5 mg) were diluted in DMSO to make 10 mM stock solution that were stored in -20 ⁰C. 1:3
serial dilutions were done in 96-well polypropylene plates with DMSO and placed in 384-well opaque
compound plates with concentrations ranging from 2mM to 0.10uM. Compound plates were sealed
with aluminum tape and stored at -20 ⁰C to avoid degradation.
HCT-116 colorectal cancer cells were chosen as our cell model because they have been shown to
overexpress miRNA-31 and are easily transfectable.56 Cells were purchased from ATCC and initially
cultured in 75-cm2 flasks (Falcon) using McCoy’s 5A modified media (Gibco) supplemented with 10% FBS
and incubated at 95% humidified air under 5% CO2 at 37°C. Cells were transitioned to DMEM High
Glucose Media (Gibco) supplemented with 10% FBS prior to use in this assay.
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The pmirGLO Dual-Luciferase miRNA target expression vector was purchased from Promega and
the reverse complement of the 5p mature miRNA-31 strand was cloned in by GenScript (sequence: 5’
AGCTATGCCAGCATCTTGCCT 3’, obtained from miRBase).The empty pmirGlo vector and pmirGlo-miRNA31 plasmid will be transfected into HCT-116 colorectal cancer cells (ATCC) at a final concentration of
0.016 μg/μL using Lipofectamine 2000 and Opti-MEM reduced serum medium (Gibco) according to
manufacturer’s protocols. The empty vector will represent 100% translation of the luciferase gene and
will be used as a positive control. Other controls for the assay will be 1% DMSO (negative control) and
IDT miR-31 inhibitor (positive control) at a final concentration of 15 nM. Upon arrival, 5 nmols of IDT
miRNA-31 inhibitor will be diluted in 50 uL autoclaved TE buffer (pH = 8) to 100 uM concentration,
aliquoted into 10 uL portions, and stored at -20 C.
Dual-Glo Luciferase Assay System was purchased from Promega (cat. no. E2920) and used to
quantify both firefly and Renilla luciferase bioluminescence signals according to manufacturer’s
protocols. Assays will be conducted in 384-well white optical bottom plates (Nunc, cat. no. 142762) and
white tape was placed on the bottom before reading the plates for bioluminescence in a Tecan Spark
multimode plate reader.
3.2.2. Transformation of pmirGLO miRNA-31 and
purification (completed)
The pmirGLO-miRNA-31 plasmid (Figure 3.3) was
transformed a JM109 competent cell line (Promega) via
heat shock. An isolated colony was selected using
ampicillin plates. The culture was grown up to 500 mL
and purified using the Endofree Plasmid Mega Kit
(Qiagen, cat. no. 12381). The vectors were stored in 1X
TAE buffer in the -20C freezer. For plasmid verification,

Figure 3.3. pmirGLO vector construct. The
inverse complement of miRNA-31-5p was
inserted between Sac1 and Sal1 cut sites
downstream of the luc2 (firefly gene). (Image
borrowed from Promega)
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the constructs were cut using HI EcoRI for 1hr at 37C, resulting in a 7350bp strand of linear plasmid.
Once digested, the vectors were run on a 0.8% agarose gel with SYBR Gold and visualized using a BioRad gel imaging system.
3.2.3. Dual-Glo Luciferase Assay protocol (proposed)
HCT-116 cells will be grown in a 75-cm2 flask and 6-well plates (Falcon) using DMEM (Gibco)
supplemented with 10% FBS (Gibco) until 70-80% confluence (5% CO2 at 37°C). Once cells reach the
desired confluence, the T-75 flask will be transfected with the pmirGLO-miRNA-31 using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocols. One well in the 6-well plate will be
transfected with the empty vector and another with pmirGLO-miRNA-31 and an ASO for miR-31 using
Lipofectamine 2000. After 24 hours, HCT-116 cells will be harvested and plated into 384-well white
optical bottom plates pretreated with Matrigel using the assay media DMEM without phenol red and
FBS. Each well will contain 10,000 cells. Plates will be centrifuged at 1000 rpm and incubated (5% CO2 at
37°C) for 4-5 hours or until they are fully adhered to the plates. Small molecules identified through Psmir
will be introduced at to each well in a dose-responsive manner. Using a pintool (V&P Scientific, Inc.), 100
nL of each compound will be transferred to each well containing 20 μL of media. We will do two
transfers (200 nL) to obtain a final maximum compound concentration of 20 μM and minimum
concentration of 1 nM. Because DMSO is toxic to cells, two transfers ensure a safe limit of 1% DMSO.
After 24 hours, Dual-Glo Luciferase substrate (Promega), which contains the substrates required for
Firefly luciferase and Renilla luciferase, will be added according to manufacturer’s protocols (1:1 media
to reagent ratio). Plates will be read at t = 10 minutes to ensure full lysis of cells.
Controls will be measured in each plate to determine Z factor (Equation 1) and to enable data
normalization.
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𝑍! = 1 −

3&𝜎" − 𝜎# (
)𝜇" − 𝜇# )

Equation 1. Z’ factor equation. ‘p’ subscript
indicates a positive control, whereas ‘n’
subscripts indicate negative controls.

Three independent experiments will be performed in quadruplicate and data will be analyzed using
nonlinear regression with variable slope (GraphPad Prism 8, Equation 2).

𝑌=

𝐵𝑜𝑡𝑡𝑜𝑚 + (𝑋$%&&'&(") )(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)
(𝑋$%&&'&(") + 𝐸𝐶50$%&&'&(") )

Equation 2. Nonlinear regression equation. EC50 is the concentration of agonist (in our case antagonist) that
gives a response half-way between Bottom and Top. Hillslope is the steepness of the family of curves and is
typically 1. Top and Bottom are plateaus in the units of the Y axis.

3.2 Results and Discussion
3.2.1. Transformation and purification results (completed)
The digested pmiRGlo purification products were run in a 1.0% agarose gel and stained with
SYBR Gold to be visualized. As shown in Figure 3.4, all products appear at 6-10 kilobases (kb), although
ranging concentrations. In the future, Lane 2, 4, 5, should be re-tested at lower concentrations in order
to determine more accurately their size. However, this showcased that the products were free of
contaminating DNA, along with being in right range of molecular weight (7350bp). As showcased in
Figure 3.4, miR-18a was also
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tested, alongside miR-31. The “scramble” vectors, as labeled in
Figure 3.4 are pmirGLO vectors of which the insert was generated
incorrectly. Instead of the reverse complement being inserted into
the pmirGLO vector, the exact sequence of the miRNA was
inserted. Therefore, there would be no miRNA binding. However,
due to the same number of bp, the vectors for the scramble and
true pmriGLO vectors are the exact same size. Moreover, the mir18a pmirGLO vector will be used in future luciferase experiments
and is not relevant to the project being discussed. However, like
the scramble vector, the mir-18a pmirGLO vector is similar in size
to the mir-31 pmirGLO vector (7350bp), plus or minus a few base

Figure 3.4. Gel confirming pmirGlomiRNA-31 transformation and
purification. Purple DNA Ladder (1),
Scramble pmirGLO- miRNA-31 (2),
Scramble pmirGLO- miRNA-18a (3),
pmirGLO- miRNA-31 (4), pmirGLOmiRNA-18a (5), pmirGLO-Empty
vector (6)

pairs. The empty vector contains the pmirGLO construct but does
not have the miRNA binding site insert. The concentrations of the vectors are listed in the Table 2.
Table 2. Concentrations of pure pmirGLO plasmids.
Sample

Amount (ug/uL)

miRNA-31 pmirGlO (1)

0.5038

miRNA-31 pmirGLO (2)

0.1941

Empty pmirGLO

0.2879

3.2.2. Luciferase assay results (not completed)
No results were obtained due to time conflicts and the Covid-19 shutdown.
3.3 Future experiments and conclusions
The transformation and purification of the pmirGlo-miRNA-31 and empty plasmids were
successful, although a new gel with lower and consistent concentrations of DNA loaded should be

19
performed. Vectors were pure and yielded working concentrations that were easily manipulated for
future experimentation. The assay itself was not optimized due time and Covid-19, however, based on
the manufacturer’s protocols and the literature I am confident that future researchers will have success
with my proposed protocol. Once optimized, future researchers will be able to screen the 14 psmir
database compounds for miR-31 inhibitory activity. This will serve as the primary assay for testing of
miRNA-31 inhibitors and that can be used with other miRNA investigated in the Teske group (i.e miRNA18a). In summary, although I did not have an opportunity to optimize my proposed luciferase assay
protocol, I was successful in transforming the designed vectors and purifying them for future studies.

CHAPTER IV: EVALUATION OF SMALL MOLECULE INHIBITION miR-31 EXPRESSION USING qRT-PCR
4.1. Background
Real time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) is an effective
method used to measure the amount of RNA (coding or noncoding) in a given sample. Essentially, qRTPCR operates by first isolating the RNA from a given sample, in this case HCT-116 cells. Once the RNA is
purified, it is reverse transcribed using a reverse transcriptase and highly specific primers for miRNA to
generate cDNA. That cDNA can then be used in qRT-PCR. Fluorescent probes bind to a sequence on the
RNA, and during each amplification step, are released, generating fluorescence. These fluorescence
values can be used to quantitatively determine the amount of nucleic material in a given sample. It is
particularly useful in screening small molecule inhibitors. In our case, an inhibitor would decrease the
amplification levels of miRNA therefore generating lower fluorescence values.
Because miRNA are short nucleotide strands (18-22 nt), the reverse transcription (RT) step
becomes difficult with the typical linear primers. Because these primers can be non-specific with such
short strands, amplification of other RNA products in addition the miRNA of interest can occur. This has
since been remedied by using stem-looped forward primer which increases the length of the miRNA
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nucleotide strand from about 22 bp to 60
bp (Figure 4.1).57 This decreases the
likelihood of nonspecific binding. Stability
of the miRNA is also an issue, especially in
the reverse transcription protocol. A
pulsed RT transcription protocol is typically
applied to fix that issue (see section 4.2.2).
Essentially, this decreases the likelihood
of miRNA degradation, due to prolonged
thermal exposure. Furthermore, it allows

Figure 4.1. Taqman qRT-PCR for miRNA. This technology for
evaluating miRNA expression uses a stem-looped RT primer
to ensure specific amplification. (borrowed from Springer,
2005)

multiple opportunities for the miRNA to bind to the stem-loop primers, resulting in increased copy DNA
(cDNA) levels. Other precautions, including avoiding multiple freeze-thaw cycles of the isolated miRNA,
and keeping samples on ice, can also be instituted.
Selecting suitable housekeeping genes (HKG) for qRT-PCR analysis is also a challenge because
amplification levels of miRNAs vary based on the cell type and environmental conditions. A suitable HKG
is one that is stable across sample types, has relatively high amplification levels, and is biochemically
similar to the target. Candidate HKGs were selected based on a thorough literature search focused on
HCT-116 cells. The four HKGs that were selected to be tested included miRNA-93, miRNA-25, SNORD44
(RNU44), and miRNA-16. Both miRNA-93 and miRNA-25 were evaluated to determine the most suitable
HKGs by Niu et al. in HCT116 and MCF-7 (breast cancer) cells.58 RNU44 was found by Morata Torifa et al.
to be an adequate candidate for comparing healthy cells to cancerous cells as a normalizer.59 miRNA-16
was find by Rinnerthaler et al. to be a suitable HKGs.60 Furthermore, miRNA-16 recommended by
Applied Biosystems as to be one of the most stably expressed miRNAs among 59 of NCI’s 60 cell lines,
which includes HCT116.61
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Note: Due to Covid-19, the psmir compounds were not tested for miRNA-31 inhibition in qRT-PCR.
4.2 Experimental Procedure
4.2.1 General reagents and instrumentation
HCT-116 cells were purchased from ATCC and cultured in 75-cm2 flasks (Falcon) using McCoy’s
5A modified media (Gibco) with 10% FBS (Gibco) and incubated at 95% humidified air under 5% CO2 at
37°C. The mirVana miRNA Isolation Kit (Invitrogen, cat. no. AM 1560), Taqman microRNA Reverse
Transcription Kit (Applied Biosystems, cat. no. 4366596), and Taqman Fast Advanced Master Mix
(Applied Biosystems, cat. no. 4444556) were utilized for this study. Probes included the HKGs: hsamiRNA-25-3p, hsa-miRNA-93-5p, RNU44 (hsa-SNORD44), and hsa-miRNA-16-1*-3p; and hsa-miRNA-315p (gene of interest [GOI]). All probes were purchased from Thermofisher Scientific. RT to produce cDNA
was accomplished using Applied Biosystems Veriti 60 Well Thermocycler. qRT-PCR was performed on an
Applied Biosystems QuantStudio 3 qRT-PCR system. Data was analyzed using GraphPad Prism 8.
4.2.2. Real Time qRT-PCR Protocol for analysis of HKGs (completed)
Cell culture for qRT-PCR
Using a 70-80% confluent 75-cm2 flask, HCT-116 cells were plated in a 24-well plate at 100,000
cells/well in 400 μL McCoy’s 5A media supplemented with 10% HI FBS. 400 μL of media was added to
empty wells to prevent evaporation while cells incubated overnight at 37 ⁰C and 5% CO2. After 24 hrs,
growth media was removed and 400 μL of Assay Media (McCoy’s 5A without HI FBS) was placed in each
well. The cells were incubated again overnight at 37 ⁰C and 5% CO2. We chose to plate cells in FBS
containing media and then replace it with media without FBS to ensure proper cell adherence and
growth prior to drugging. Although, we did not drug cells with small molecules in this section it was
important to do the same procedure while testing HKGs.
miRNA isolation form HCT-116 cells
After overnight incubation to FBS-free media, miRNA was isolated using the mirVanaTM miRNA
isolation kit following the manufacturer’s protocol. Media was aspirated from each well and 500 μL of
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cold PBS was added carefully as to not disrupt the cells. The PBS was removed and 600 μL of the
Lysis/Binding solution was added to each well and mixed thoroughly. The lysates were transferred to 2
mL microcentrifuge tubes. 60 μL (1/10 volume) of miRNA homogenate additive was added to each tube
containing the lysate and pipetted in order to generate a homogenous mixture. Microcentrifuge tubes
were then placed on ice for 10 minutes. 600 μL of an Acid-Phenol: Chloroform was added to each
microcentrifuge tube and vortexed for 30-60 seconds. The tubes were then centrifuged for 5 mins at
10,000 x g at room temperature. The upper (aqueous phase) was removed and transferred to a fresh
tube. Elution solution provided in the kit or nuclease-free water was heated to 95 ⁰C before being used.
750 μL of 100% ethanol was added to the aqueous phase containing the isolated miRNA. Tubes were
mixed by inversion. A filter cartridge was placed into labeled collection tubes for each sample and the
lysate-ethanol mixture was added to the filter cartridge (700 μL maximum). The collection tubes were
centrifuged for 15 seconds at 10,000 x g to pass the mixture through the filter and was repeated until all
the liquid had passed through. 700 μL of miRNA Wash Solution 1 was added to the filter cartridge and
centrifuged for 5-10 seconds to pass the solution through the filter. Two portions of 500 μL of Wash
Solution 2/3 were added to the cartridges, centrifuging at 10, 00 x g for 1 min after each portion. After
the washes were completed, the tubes were centrifuged at 10,000 x g for 1 min in order to remove
residual fluid. The filter cartridge was then transferred to a fresh, labeled collection tube and 100 μL of
preheated Elution Solution (or nuclease-free water) was applied to the filter. The cap was closed and
centrifuged at 10,000 x g for 1 minute. RNA was stored for up to one week at -20C.
Reverse Transcription
Reverse Transcription of the miRNAs was carried out using the TaqMan MicroRNA Reverse
Transcription Kit. The reverse transcription components were thawed on ice and centrifuged in order to
collect on the bottom. The RT master mix was prepared with 0.15 μL of 100 mM dNTPs, 1.00 μL of 50
U/nL MultiScribe Reverse Transcriptase, 1.50 μL of 10X RT Buffer, 0.19uL of 20 U/nL RNase Inhibitor and
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4.16 μL of Nuclease Free Water. 7uL of the Reaction Mix was placed in a RT tube along with 5 μL of the
isolated miRNA. 3 μL of 5X RT Primer was added to the tube, specific for the miRNA or HKGs, to make a
final solution of 15 μL. Thermal Cycling was carried out using the Applied Biosystems Veriti 60 Well
Thermocycler according to the Pulse RT protocol in Table 3. cDNA products were not stored, as a
stability experiment has not been performed.
Table 3. Pulsed RT protocol used in Applied Biosystems Veriti 60 Well Thermocycler.
Step
Temperature
Time

Reverse Transcription (1)

16 ⁰C

Cycles

30 mins

1

30 mins

60

30 ⁰C for 30s
Reverse Transcription (2)

42 ⁰C for 30s
50 ⁰C for 1s

Stop Reaction

85 ⁰C

5 mins

1

Hold

4 ⁰C

Hold

N/A

qRT-PCR
qRT-PCR was performed using the TaqMan Fast PCR Master Mix. The master mix was inverted,
centrifuged, and placed on ice. qRT-PCR was run with the GOI (miRNA-31) and HKG (hsa-miRNA-25-3p,
hsa-miRNA-93-5p, RNU44 (hsa-SNORD44), and hsa-miRNA-16-1*-3p), a nuclease-free water control, a
no reverse transcriptase (miRNA) control, and a no template control (master mix). Each PCR reaction
contained 0.50 μL of the TaqMan miRNA Assay (probe), 5.00 μL of the TaqMan Universal PCR Master
Mix, 3.50 μL of Nuclease Free Water, and 1.00uL of the cDNA Template. The PCR plate was kept on ice
during this process in order to prevent degradation. The master mix, cDNA, and probe were all mixed
into a single tube before transferring to the PCR plate, making sure to add the probe last. After all
components were mixed together, 10 μL of each reaction was added into the appropriate wells, making
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sure to avoid creating bubbles. The plates were sealed with optical adhesive film and centrifuged at
1000 x g for two minutes. Samples were run according to the protocol listed in Table 4 in an Applied
Biosystems QuantStudio 3 qRT-PCR system. Each sampled was tested in triplicate.
Table 4. qRT-PCR protocol used for Taqman assays in the Applied Biosystems QuantStudio 3 qRT-PCR system.
Step
Temperature
Time
Cycles
UNG Activation

50 ⁰C

2 mins

1

Enzyme Activation

95 ⁰C

20 secs

1

Denature

95 ⁰C

1 sec

45

Anneal

60 ⁰C

20 secs

45

4.3 Results and Discussion
4.3.1 Determination of suitable HKG (completed)
Multiple HKG candidates were chosen based on thorough literature search. A suitable HKG is
one that is biochemically similar to the target, has relatively high expression levels, and is stable across
sample types. hsa-miRNA-25-3p, hsa-miRNA-93-5p, RNU44 (hsa-SNORD44), and hsa-miRNA-16-1*-3p
and GOI hsa-miRNA-31 were all evaluated using the qRT-PCR protocol listed in the experimental section.
The comparative Ct method used to evaluate the paper by Silver et. al to evaluate the variability of HKGs
within a given assay.62 The calculations for this graph were performed in GraphPad Prism v8 and
calculated in the following manner as showcased in Equations 3 and 4.
∆𝐶𝑡(𝐻𝐺𝑋) = 𝐶* (𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡) − 𝐶* (ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒)
∆"+ ($%&)
∆"+ ($%()

Equation 3

Equation 4

Equation 3 and 4. ∆CT calculation. ∆CT calculated by determining the
difference between the target gene (miRNA-31) and the HKG being
evaluated. These values where then used to generate ratios between two
HKGs.
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These values were then used in order to generate two graphs. Figure 4.2 showcases the Ct
values for the given genes at various cell counts. This demonstrates the Ct values for the given genes
based on cell count. As cell count increases, the number of amplicons should increase, therefore
decreasing the Ct value. This happens in most of the genes evaluated, with the exception of RNU44,
specifically, within 40,000 cells. A possible reason for this is that the 20,000 cell sample, and the 40,000
cell sample were improperly placed, therefore, resulting in higher Ct values for an larger number of
amplicons. If the 20,000 cell sample and the 40,000 cell sample were to be switched, the Ct would
decrease along a predicted path. Other possible reasons for this include pipetting errors, and the high
variability of RNU44. Figure 4.3, the lines below and above the box represent the standard deviation of
each sample and the boxes represent the range of values for a given ratio. This plot showcases which
HKGs exhibit the highest variability in a given assay of the same cell type. For example, miRNA-25
showcases relatively low variability when compared to the other HKGs, except when exposed to RNU44,
this is also the same for miRNA-93 and miRNA-16. From this, it can be reasonably concluded that RNU44
is variable across the assay, indicating a wide range of expression levels. This should be eliminated as an
HKG candidate, due to the fact that the relative expression levels vary so greatly. It was from this data
that miRNA-16 and miRNA-93 were chosen as suitable HKGs. miRNA-25 was not selected as a candidate
for housekeeping studies, as miRNA-16 was established to be one of the most stably expressed genes in
59 of NCI-60 cell lines. Furthermore, miRNA-93 had a slightly lower Ct value than miRNA-25.

26

Figure 4.2. Ct values obtained during evaluation of HKGs for miR-31 analysis.
Expression levels of each HKG and GOI were evaluated from different increasing amounts of cells.

T

Figure 4.3. Variability assessment via comparative ΔCt. The HKG were compared by ΔCT
values leading to the conclusion that miRNA-25, miRNA-16, or miRNA-93 would be suitable
HKGs for studying miRNA-31 expression.

4.3.2. Small molecule compounds effect on miR-31 expression in real time qRT-PCR (not completed)
No results were obtained due to conflicts in time and the Covid-19 shutdown.
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4.4. Future experiments and conclusions
Future experiments will include introducing the psmir small molecules to the HCT-116 cells and
evaluating miR-31 expression levels. Drug solutions will be introduced using dose-response
concentrations ranging from 20 μM – 1 nM and will be incubated for 24 hours.
The determination of suitable HKGs for qRT-PCR normalization was successful. This
experimentation resulted in miRNA-31 and miRNA-16 as being selected for adequate normalization.
Furthermore, the qRT-PCR assay was optimized, and works adequately under the current methods. As
stated in section 3.3, the miRNA-31 qRT-PCR assay will be used as a secondary assay for the verification
of the luciferase assay results. Moreover, this assay will be used as a secondary assay for other projects,
including that of miRNA-18a. Notably, one freeze-thaw step was tested for the assay and did not have a
significant impact on amplification levels. The recommendation was not exceeded. Moreover, it was
determined that the stability of the miRNA had a significant impact on amplification levels. Initially, the
standard PCR mix with a run time of two hours was being used and under these conditions, Ct values
always exceeded 32. With the switch to the fast PCR protocol, reduction to one-freeze thaw step, and
shift to a pulsed reverse transcription protocol, the Ct values reached appropriate levels.
CHAPTER V: CONCLUSION
The steps taken in terms of literature searches and preparing reagents proves that these studies
can be accomplished in the future. The psmir base established a relationship between various FDAapproved compounds and their possible inhibitory effect on miRNA-31. Based on this, and fundamental
connection between their structures, it is believed that the molecules will have an inhibitory effect on
miRNA-31. Whether the level of inhibition will be respective to their relative score values is unknown
but will be evaluated in future experiments.
The experimentation through the qRT-PCR led to an optimized standard operating protocol and
the determination of HKGs. Through this experimentation, it is perceived that miRNA-16 and miRNA-93
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will serve as reliable genes for assay normalization. Moreover, the data seems to indicate that a reduced
number of cells could be used for future experiments, based on the relatively high Ct values. This is
further supported by the manufacturer’s protocol which states as low as 100 cells can give reproducible
results. Stability of the miRNA was found to be a significant issue in the initial stages of qRT-PCR. It is
now understood that a single freeze-thaw, along with the fast PCR protocol, contributed to increased
amplicon levels.
The necessary vectors for the luciferase assay were produced and successfully purified. The use
of a 500 mL culture, and the EndoFree Plasmid Mega Kit proved to be a suitable method for generating
and isolating the pmirGLO vectors. Future testing and optimization are needed in order for the assay to
be in working condition.
Overall, the conclusion drawn from these experiments set the foundation for investigating the
miRNA-31 inhibition via the compounds selected from psmir.
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